ACE2 and infection: These mutations, located at the interfaces of the RBD-ACE2/antibody complexes, have been shown to increase S binding to ACE2 and decrease its recognition by neutralizing antibodies (28, 43–45), leading to the enhanced infection efficacy and transmissibility for the variants.